ZGNX Zogenix Inc.

41.44
-0.43  -1%
Previous Close 41.87
Open 41.69
Price To Book 3.23
Market Cap 1739154707
Shares 41,968,019
Volume 571,696
Short Ratio
Av. Daily Volume 577,343

SEC filingsSee all SEC filings

  1. 8-K - Current report 181214017
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170534
  3. 8-K - Current report 181169644
  4. 8-K - Current report 181110630
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181062825

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation announced November 29, 2017.
ZX008
Lennox-Gastaut syndrome
Approved July 16, 2009.
Sumavel
Migraine
Phase 3 data released July 12, 2018. Primary endpoint met.
ZX008 - Study 1504
Dravet syndrom
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Approved October 25, 2013.
Zohydro ER
Moderate to severe pain
Phase 3 data released September 29, 2017 - primary endpoint met. Additional data rleased at American Epilepsy Society Annual Meeting December 3, 2017.
ZX008 - (Study 1)
Dravet syndrom
Approved January 30, 2015.
Abuse deterrent formulations of Zohydro ER
Moderate to severe pain

Latest News

  1. Edited Transcript of ZGNX earnings conference call or presentation 8-Nov-18 9:30pm GMT
  2. Here is What Hedge Funds Think About Zogenix, Inc. (ZGNX)
  3. Final trades: Home Depot, Target, Charter Communications,...
  4. What Kind Of Share Price Volatility Should You Expect For Zogenix Inc (NASDAQ:ZGNX)?
  5. Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
  6. Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome
  7. Zogenix Presents Positive Findings on the Impact of Treatment with FINTEPLA® (ZX008) on Everyday Executive Function in Patients with Dravet Syndrome
  8. Cannabis-Based Drug (Still) Helps Epilepsy, but How Safe Is It?
  9. Zogenix to Participate in the Global Mizuho Investor Conference 2018
  10. Zogenix: 3Q Earnings Snapshot
  11. Zogenix Provides Corporate Update and Reports Third Quarter Financial Results
  12. Zogenix to Present at Stifel 2018 Healthcare Conference
  13. The First Cannabis-Derived Drug Is Now on Pharmacy Shelves
  14. Zogenix to Release Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 8
  15. Zogenix Inc (NASDAQ:ZGNX): Is Breakeven Near?
  16. Zogenix Sees Hammer Chart Pattern: Time to Buy?
  17. Health Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners

SEC Filings

  1. 8-K - Current report 181214017
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170534
  3. 8-K - Current report 181169644
  4. 8-K - Current report 181110630
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181062825
  6. 8-K - Current report 181002309
  7. 424B5 - Prospectus [Rule 424(b)(5)] 181002097
  8. 424B5 - Prospectus [Rule 424(b)(5)] 18995647
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18995454
  10. 8-K - Current report 18995094